ATE147626T1 - Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung - Google Patents

Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung

Info

Publication number
ATE147626T1
ATE147626T1 AT90911118T AT90911118T ATE147626T1 AT E147626 T1 ATE147626 T1 AT E147626T1 AT 90911118 T AT90911118 T AT 90911118T AT 90911118 T AT90911118 T AT 90911118T AT E147626 T1 ATE147626 T1 AT E147626T1
Authority
AT
Austria
Prior art keywords
hexocyclium
telenzepine
pirenzepine
sila
methoxy
Prior art date
Application number
AT90911118T
Other languages
English (en)
Inventor
Alan M Laties
Richard A Stone
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/522,241 external-priority patent/US5122522A/en
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE147626T1 publication Critical patent/ATE147626T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT90911118T 1989-06-21 1990-06-14 Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung ATE147626T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36929389A 1989-06-21 1989-06-21
US07/522,241 US5122522A (en) 1989-06-21 1990-05-11 Treatment and control of ocular development

Publications (1)

Publication Number Publication Date
ATE147626T1 true ATE147626T1 (de) 1997-02-15

Family

ID=27004525

Family Applications (3)

Application Number Title Priority Date Filing Date
AT94112616T ATE183085T1 (de) 1989-06-21 1990-06-14 Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten
AT96108497T ATE203666T1 (de) 1989-06-21 1990-06-14 Verwendung eines muskarinantagonists zur herstellung eines medikaments für die behandlung und regulierung der augenentwicklung
AT90911118T ATE147626T1 (de) 1989-06-21 1990-06-14 Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT94112616T ATE183085T1 (de) 1989-06-21 1990-06-14 Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten
AT96108497T ATE203666T1 (de) 1989-06-21 1990-06-14 Verwendung eines muskarinantagonists zur herstellung eines medikaments für die behandlung und regulierung der augenentwicklung

Country Status (9)

Country Link
US (2) US5356892A (de)
EP (1) EP0478694B1 (de)
JP (4) JP3165436B2 (de)
AT (3) ATE183085T1 (de)
CA (1) CA2058768C (de)
DE (3) DE69029734T2 (de)
DK (1) DK0737475T3 (de)
ES (2) ES2136686T3 (de)
WO (1) WO1990015604A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
ATE183085T1 (de) * 1989-06-21 1999-08-15 Univ Pennsylvania Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten
WO1993013777A1 (en) * 1992-01-21 1993-07-22 Merck & Co., Inc. Method of using m1-selective antimuscarinic pyridobenzodiazepinones in axial myopia therapy
US5716952A (en) * 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth
US5756508A (en) * 1995-10-31 1998-05-26 Merck & Co., Inc. Muscarine antagonists
CA2276287C (en) * 1997-01-06 2007-10-30 Klaus Trier Aps Screening method for compounds active in treating myopia and hypermetropia
US6291466B1 (en) 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
WO2001052832A1 (en) * 2000-01-18 2001-07-26 Valley Forge Pharmaceuticals, Inc. Ocular growth and nicotinic antagonists
CN1509172A (zh) * 2001-05-25 2004-06-30 ά����ҩ��˾ 哌仑西平眼用凝胶剂
ITUB20160876A1 (it) 2016-02-19 2017-08-19 Dambrosio Enzo Maria Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l'uso in prevenzione/ arresto di miopia assiale nell’uomo

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU188852B (en) * 1983-03-16 1986-05-28 Richter Gedeon Vegyeszeti Gyar Rt,Hu Process for producing thiazolidine derivatives active against gastric ulcer and intestinal ulcer
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
ATE183085T1 (de) * 1989-06-21 1999-08-15 Univ Pennsylvania Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten
US5122522A (en) * 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
US5360801A (en) * 1989-06-21 1994-11-01 The Trustees Of The University Of Pennsylvania Pharmacological stimulation of eye growth
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth

Also Published As

Publication number Publication date
DK0737475T3 (da) 2001-10-08
CA2058768C (en) 2004-08-03
ATE183085T1 (de) 1999-08-15
DE69033246T2 (de) 1999-12-02
EP0478694A1 (de) 1992-04-08
DE69033246D1 (de) 1999-09-16
DE69033775D1 (de) 2001-09-06
DE69029734D1 (de) 1997-02-27
ES2136686T3 (es) 1999-12-01
JPH05500502A (ja) 1993-02-04
DE69033775T2 (de) 2001-11-15
JP3165436B2 (ja) 2001-05-14
WO1990015604A1 (en) 1990-12-27
CA2058768A1 (en) 1990-12-22
US5637604A (en) 1997-06-10
JP2000204049A (ja) 2000-07-25
US5356892A (en) 1994-10-18
HK1007681A1 (en) 1999-04-23
EP0478694B1 (de) 1997-01-15
JP2001081046A (ja) 2001-03-27
EP0478694A4 (en) 1992-07-29
JP2004075695A (ja) 2004-03-11
ATE203666T1 (de) 2001-08-15
DE69029734T2 (de) 1997-05-28
JP3461778B2 (ja) 2003-10-27
ES2159661T3 (es) 2001-10-16

Similar Documents

Publication Publication Date Title
DE69911620T2 (de) Muskarinische antagonisten zur behandlung von presbyopie
Hensler et al. A quantitative autoradiographic study of serotonin1A receptor regulation: Effect of 5, 7-dihydroxytryptamine and antidepressant treatments.
DE236684T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
ATE111733T1 (de) Verwendung von nikotin zur herstellung eines kit zur behandlung von krankheitszuständen, die auf eine nikotinbehandlung ansprechen.
AU645023B2 (en) Compositions and method for treating painful, inflammatory or allergic disorders
DE69029734D1 (de) Verwendung von Pirenzepine, Telenzepine oder O-Methoxy -sila-hexocyclium zur Herstellung eines Medikaments zur BEHANDLUNG UND REGULIERUNG DER AUGENENTWICKLUNG
DE68912419D1 (de) Verwendung von Uridin zur Behandlung nervöser Störungen.
KR920702622A (ko) 안구 발육의 치료 및 조절
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
DE69209128D1 (de) Verwendung von Indazol-Methoxyalkansäure zur Herstellung eines Arzneimittels zur Behandlung von Autoimmunkrankheiten
Cohn et al. Guanosine 3′, 5′-monophosphate: A central nervous system regulator of analgesia
Nielsen et al. Responses to noradrenaline in human subcutaneous resistance arteries are mediated by both α1‐and α2‐adrenoceptors
Raab et al. Drug action upon myocardial epinephrine-sympathin concentration and heart rate (nitroglycerine, papaverine, priscol, dibenamine hydrochloride)
Loeb et al. Liposome‐entrapped γ‐aminobutyric acid inhibits isoniazid‐induced epileptogenic activity in rats
JPS5781486A (en) Benzo(ij)quinolidine-2-carboxylic acid derivative
BR9708922A (pt) Piridil-e pirimidil-piperazinas no tratamento de doenças causadas por substâncias usadas em excesso
Kimoto et al. Actions of the alpha-1 adrenoceptor blocker bunazosin on the norepinephrine-induced contraction of smooth muscles in the rabbit proximal urethra.
ATE190628T1 (de) Zusammensetzungen von wachstumsfaktoren, herstellung und verwendung
CA2369054A1 (en) Treatment and control of ocular development
Leopold Trends in Ocular Therapy: The 23rd Sanford S. Gifford Memorial Lecture
ATE24834T1 (de) Verwendung von beta-(1-adamantyl)-alpha, alphadimethylethylamin zur herstellung eines arzneimittels zur behandlung von otitis externa bei hunden.
ATE162516T1 (de) Nichtmetabolisierbare clomiphene-analoge zur behandlung von tamoxifen-resistenten tumoren
ATE80998T1 (de) Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
Dickinson et al. Effects of idazoxan on 5-hydroxytryptamine-mediated behaviour in the mouse and rat
Rengo et al. Studies on the nature of the vasodilator fibers running in the lumbar sympathetic chain of the dog

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties